A medical swab is a medicated absorbent pad, stick, or material used in the medical industry as a single-use device. It is typically composed of premium pharmaceutical-grade materials, such as sterile cotton, rayon, polyester, and foam, further sterilized by ethylene oxide gas or gamma irradiation before distribution. They are widely used for wound sanitation, surgical procedures, sample collection, and first aid because they contain absorbent materials with medicinal properties.
The target demographic medical swabs are intended for is seeing significant growth due to multiple variables, such as the expanding elderly population with acute and chronic illnesses, the rise in demand for laboratory testing, and other contributing factors. It is estimated by the World Health Organization (WHO) that over 1.4 million individuals are diagnosed with healthcare-associated infections (HAIs) at any given point in time.
Patients can contract HAIs through exposure to bacteria, viruses, spores, or fungi through contact with the hands of healthcare employees, contaminated environmental surfaces, catheter insertions, and other patients. This is not limited to patients alone, as physicians are also susceptible to these infections, which is one of the primary motivations for swab tests in developed nations. One of the key growth drivers for the medical swabs market is the increase in infectious disease cross-infections and pandemics.
Several medical swab manufacturing startups have introduced new variants with distinctive designs that can replace deep nasopharyngeal swabs. Test at Home Pte. Ltd. (TAH), an India- and Singapore-based startup supported by Antler, a global VC firm, introduced a lollipop-like swab for collecting saliva samples for COVID-19 testing. The company intends to supplant the nasal swab technique for accurate COVID-19 testing with a less invasive and painless saliva collection method. The company conducted clinical trials on patients in India in partnership with the National University of Singapore and Datar Cancer Genetics (UK-Germany-India). The results were extremely encouraging, with a 95% accuracy rate compared to conventional nasal swabs. Thus, the new generation of sample collection swabs creates opportunities for market expansion.
Asia-Pacific is the most significant global medical swabs market shareholder and is anticipated to grow substantially during the forecast period. The expansion of the elderly population, the prevalence of chronic diseases, and the rate of surgical procedures in hospitals, ASCs, and other healthcare facilities are driving market growth. The majority of the region's elderly suffer from chronic conditions, like cancer and cardiovascular disease, which frequently necessitate surgical intervention. Consequently, the prevalence of such chronic conditions has boosted the demand for diagnostic tests in the region, thereby surging the demand for medical samples.
In addition, the high population and demand for population-scale testing have increased the market's demand for medical samples. By 2025, an estimated 226 million seniors (65 or older) will reside in 710 metropolitan areas/cities in Asia-Pacific, representing 11.4% of the total population. This demographic shift toward an aging population is driving up the region's hospital admissions rate and increasing the demand for medical devices in hospitals.
The key global medical swabs market players are Puritan, COPAN Diagnostics, GPC Medical, FortiusBio, FL Medical, Changzhou Medical Appliances General Factory, Anhui Jiaxin Medical Products, Origin, Becton Dickinson and Company, CML Biotech, AdvaCare Pharma, and others.